08:00 , Jan 24, 2011 |  BioCentury  |  Regulation

Arguing for Avastin

Information made public last week by Genentech Inc. suggests FDA moved the goalposts between granting accelerated approval to Avastin bevacizumab to treat metastatic breast cancer in 2008 and proposing to withdraw the indication last month....
07:00 , Apr 10, 2006 |  BC Week In Review  |  Company News

Valera, Anthra deal

VLRX acquired rights to Valstar valrubicin from Anthra for $600,000 plus potential milestones and royalties. The anthracycline derivative is approved to treat refractory carcinoma in situ of the blabber in patients for whom removal of...
07:00 , Jul 24, 2000 |  BC Week In Review  |  Clinical News

Valtaxin valrubicin chemotherapeutic anthracycline derivative regulatory update

Canada granted marketing approval for PLB's Valtaxin for intravesical therapy of refractory carcinoma in situ (CIS) of the bladder. PLB acquired Canadian rights to the compound, which is marketed in the U.S. under the name...
07:00 , Jul 18, 2000 |  BC Extra  |  Company News

Paladin Labs receives approval for Valtaxin

Paladin (TSE:PLB) received Canadian marketing approval for Valtaxin valrubicin, a chemotherapeutic anthracycline derivative, for intravesical therapy of refractory carcinoma in situ (CIS) of the bladder. PLB acquired Canadian rights to the compound, which is marketed...
08:00 , Feb 14, 2000 |  BC Week In Review  |  Company News

Cytogen management update

Cytogen Corp. (CYTO), Princeton, N.J.   Business: Cancer, Diagnostics/Imaging   Hired: Nicholas Borys as VP of medical affairs, formerly VP and medical director at Anthra Pharmaceuticals Inc.  ...
08:00 , Feb 7, 2000 |  BC Week In Review  |  Clinical News

Valstar valrubicin regulatory update

Canada accepted for filing Anthra's new drug submission for Valstar, a chemotherapeutic for intravesical therapy of refractory carcinoma in situ of the bladder. PLB has exclusive rights in Canada to the product, which is approved...
07:00 , Oct 25, 1999 |  BC Week In Review  |  Company News

Anthra, Paladin deal

PLB received exclusive rights in Canada to Anthra’s Valstar valrubicin, a chemotherapeutic for intravesical therapy of refractory carcinoma in situ of the bladder. Anthra received a $1 million equity investment from PLB, and is eligible...
07:00 , Apr 5, 1999 |  BioCentury  |  Finance

The barber's chairman

Ebb & Flow The barber's chairman Meanwhile, Anthra cited market conditions for withdrawing its NASDAQ IPO. The company is starting to generate royalty revenue, as partner Medeva launched Anthra's Valstar valrubicin in the U.S. in...
08:00 , Feb 8, 1999 |  BC Week In Review  |  Company News

Anthra, Medeva Pharmaceuticals Inc. sales and marketing update

Medeva began U.S. sales of Anthra's Valstar valrubicin to treat carcinoma in situ of the bladder in patients refractory to Bacillus Calmette-Guerin and who are contraindicated to receive cystectomies. Anthra will receive royalties. Medeva Pharmaceuticals...
07:00 , Oct 5, 1998 |  BC Week In Review  |  Clinical News

Anthra, Medeva Pharmaceuticals Inc. regulatory update

The FDA granted Orphan Drug status and marketing approval for Valstar , Anthra's anthracycline derivative valrubicin to treat carcinoma in situ of the bladder in patients who are refractory to BCG therapy and for whom...